Thrombosis and Haemostasis, Table of Contents Thromb Haemost 2013; 110(01): 04DOI: 10.1160/TH13-05-0362 Invited Editorial Focus Schattauer GmbH Dabigatran has the upper hand on warfarin Markus Bender 1 Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA › Author Affiliations Recommend Article Abstract Buy Article Refers to: Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemiaThromb Haemost 2013; 110(07): 153-161DOI: 10.1160/TH12-12-0942 Full Text References References 1 Deedwania P, Huang G. An update on antithrombotic therapy in atrial fibrillation: The role of newer and emergent drugs. Rev Cardiovasc Med 2012; 13: 104. 2 Connolly S, Ezekowitz M, Yusuf S. et al. Committee R-LS, Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009; 361: 1139-1151. 3 Watanabe M, Siddiqui F, Qureshi A. Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment. Neurocritical Care 2012; 16: 203-209. 4 Sun L, Zhou W, Ploen R. et al. Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemia. Thromb Haemost 2013; 110: 153-161.
